دورية أكاديمية
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial
العنوان: | Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial |
---|---|
المؤلفون: | Romera, Alvaro, Peredpaya, Sergiy, Shparyk, Yaroslav, Bondarenko, Igor, Mendonça Bariani, Giovanni, Abdalla, Kathia Cristina, Roca, Enrique, Franke, Fábio, Melo Cruz, Felipe, Ramesh, Anita, Ostwal, Vikas, Shah, Pradeep, Rahuman, Sajeed Abdul, Paravisini, Alexandra, Huerga, Camino, Del Campo García, Ana, Millán, Susana |
المصدر: | In The Lancet Gastroenterology & Hepatology December 2018 3(12):845-855 |
قاعدة البيانات: | ScienceDirect |
كن أول من يترك تعليقا!